MOESM9 of Transcriptomic profiling and quantitative high-throughput (qHTS) drug screening of CDH1 deficient hereditary diffuse gastric cancer (HDGC) cells identify treatment leads for familial gastric cancer Ina Chen Lesley Mathews-Greiner Dandan Li Abisola Abisoye-Ogunniyan Satyajit Ray Yansong Bian Vivek Shukla Xiaohu Zhang Raj Guha Craig Thomas Berkley Gryder Athina Zacharia Joal Beane Sarangan Ravichandran Marc Ferrer Udo Rudloff 10.6084/m9.figshare.c.3768611_D9.v1 https://springernature.figshare.com/articles/presentation/MOESM9_of_Transcriptomic_profiling_and_quantitative_high-throughput_qHTS_drug_screening_of_CDH1_deficient_hereditary_diffuse_gastric_cancer_HDGC_cells_identify_treatment_leads_for_familial_gastric_cancer/4959398 Additional file 9: Figure S7. Increased induced cell death upon treatment with topoisomerase II and dual PI3K/mTOR in hereditary c.1380delA CDH1 SB.mhdgc-1 versus sporadic gastric cancer cell lines. Caspase 3/7 levels after 24 h of treatment with 1 µM mitoxantrone, 1 µM etoposide, or 1 µM PI-103 normalized to DMSO-treated control is shown (standard errors of the mean from at least 2 independent experiments done in triplicate shown). 2017-05-01 05:00:00 Hereditary diffuse gastric cancer (HDGC) High throughput drug screening Therapeutic leads c.1380delA CDH1 gastric cancer cells Differential gene expression profiling